Amylyx Pharmaceuticals, Inc.
Oral small-molecule therapeutic for post-bariatric hypoglycemia
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2014
- Latest Form D
- $30M, Jul 2020
- Total capital
- $51.3M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $51.3M
- 6 Form D · last Jul 2020
- 76 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 9
- 31 pending · first 2018
- Rank in peer group#179 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$30M
- Private capital raisedForm D · SEC · 5th filing$937K
- Private capital raisedForm D · SEC · 4th filing$13M
- Private capital raisedForm D · SEC · 3rd filing$1.8M
- Private capital raisedForm D · SEC · 2nd filing$4.1M
- Private capital raisedForm D · SEC · 1st filing$1.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#179 · top 12%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Felix Von CoerperDirectorNamed in SEC Form D filings
- George MilneDirectorNamed in SEC Form D filings
- George M. Milne, PH.D.DirectorNamed in SEC Form D filings
- Isaac ChengDirectorNamed in SEC Form D filings
- Joshua CohenExecutive Officer, DirectorNamed in SEC Form D filings
- Justin KleeExecutive Officer, DirectorNamed in SEC Form D filings
Show all 9 people
- Peter FinnExecutive OfficerNamed in SEC Form D filings
- Stephen ChubbDirectorNamed in SEC Form D filings
- Walter GilbertDirectorNamed in SEC Form D filings
What it has protected
USPTO · 9 granted of 40- PendingTreatment Of Post-bariatric HypoglycemiaUSPTOApplication 19420848
- PendingCompositions For Improving Cell Viability And Methods Of Use ThereofUSPTOApplication 18952187
- PendingCompositions Of Bile Acids And Phenylbutyrate CompoundsUSPTOApplication 19021426
Show all 40 patent records
- Treatment Of Post-bariatric HypoglycemiaJun 4, 2026 · Application 19420848Pending
- Compositions For Improving Cell Viability And Methods Of Use ThereofSep 4, 2025 · Application 18952187Pending
- Compositions Of Bile Acids And Phenylbutyrate CompoundsJul 10, 2025 · Application 19021426Pending
- Compositions Of Bile Acids And Phenylbutyrate CompoundsMar 11, 2025 · US 12,246,027Granted
- Methods And Compositions For Treating Amyotrophic Lateral SclerosisFeb 20, 2025 · Application 18443821Pending
- Compositions And Methods For The Treatment Of Various DiseasesJan 30, 2025 · Application 18780691Pending
- Combination Of A Bile Acid And A Phenyl Butyrate Compound For The Treatment Of Neurodegenerative DiseasesJan 16, 2025 · Application 18707761Pending
- Compositions For Improving Cell Viability And Methods Of Use ThereofJan 7, 2025 · US 12,186,330Granted
- Methods And Compositions For Treating Amyotrophic Lateral SclerosisNov 12, 2024 · US 12,138,272Granted
- Compositions Of EXENDIN-4 DerivativesSep 26, 2024 · Application 18471413Pending
- Treatment Of Congenital Hyperinsulinism With AvexitideSep 19, 2024 · Application 18572074Pending
- Methods And Compositions For Treating Amyotrophic Lateral SclerosisMay 2, 2024 · Application 18372753Pending
- Methods and Compositions for Treating Amyotrophic Lateral SclerosisMar 28, 2024 · Application 18241482Pending
- Oligonucleotide Compositions And Methods ThereofMar 28, 2024 · Application 18314761Pending
- Oligonucleotide Compositions And Methods ThereofMar 28, 2024 · Application 18356591Pending
- Methods And Compositions For Treating Amyotrophic Lateral SclerosisNov 23, 2023 · Application 17746458Pending
- Methods And Compositions For Treating Amyotrophic Lateral SclerosisSep 7, 2023 · Application 17684845Pending
- Compositions Of Bile Acids And Phenylbutyrate CompoundsFeb 21, 2023 · US 11,583,542Granted
- Compositions Of Bile Acids And Phenylbutyrate CompoundsJan 24, 2023 · US 11,559,533Granted
- Methods And Compositions For Treating Various DisordersMay 19, 2022 · Application 17591783Pending
- Methods And Compositions For Treating Various DisordersMay 19, 2022 · Application 17591808Pending
- Methods And Compositions For Treating Various DisordersMay 19, 2022 · Application 17591798Pending
- Methods And Compositions For Treating Various DisordersMay 19, 2022 · Application 17591849Pending
- Methods And Compositions For Treating Various DisordersMay 19, 2022 · Application 17591724Pending
- Methods And Compositions For Treating Various DisordersMay 19, 2022 · Application 17591813Pending
- Methods And Compositions For Treating Various DisordersMay 19, 2022 · Application 17591727Pending
- Methods And Compositions For Treating Various DisordersMay 19, 2022 · Application 17591777Pending
- Compositions For Improving Cell Viability And Methods Of Use ThereofApr 14, 2022 · Application 17557606Pending
- Avexitide For The Treatment Of Hyperinsulinemic HypoglycemiaNov 4, 2021 · Application 17285039Pending
- Compositions For Improving Cell Viability And Methods Of Use ThereofJul 27, 2021 · US 11,071,742Granted
- Methods And Compositions For Treating Various DisordersJun 24, 2021 · Application 17006601Pending
- Compositions For Improving Cell Viability And Methods Of Use ThereofDec 8, 2020 · US 10,857,162Granted
- Compositions For Improving Cell Viability And Methods Of Use ThereofJul 23, 2020 · Application 16838975Pending
- Compositions For Improving Cell Viability And Methods Of Use ThereofApr 9, 2019 · US 10,251,896Granted
- Compositions For Improving Cell Viability And Methods Of Use ThereofJan 23, 2018 · US 9,872,865Granted
- Methods And Compositions For Treating Wolfram SyndromeApplication 63631878Pending
- GLP-1R Antagonism To Improve Nutrition Following Gastrointestinal SurgeryApplication PCTUS2024025627Pending
- Methods And Compositions For Treating Wolfram SyndromeApplication 63709828Pending
- Compositions And Methods For The Treatment Of Various DiseasesApplication PCTUS2024039119Pending
- Methods And Compositions For Treating Wolfram SyndromeApplication PCTUS2025019007Pending
Related companies, and why
- Alpheus MedicalSimilar federal contract value in Biotech · null in contracts
- IN8BIO, INC.Similar federal contract value in Biotech · null in contracts
- Convergent TherapeuticsSimilar federal contract value in Biotech · null in contracts
- CODEXIS, INC.Similar federal contract value in Biotech · null in contracts
- SurrozenSimilar federal contract value in Biotech · null in contracts
- Clene Nanomedicine, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .